Core Viewpoint - Hutchison China MediTech Limited (和黄医药) shares rose over 7%, reaching HKD 26.96 with a trading volume of HKD 352 million, following the announcement of a conference in Shanghai to share R&D progress [1] Group 1: Company Developments - The company will hold a conference on October 31, 2025, in Shanghai to discuss its latest R&D advancements, which will be live-streamed [1] - Dr. Shi Ming, the Executive Vice President and Chief Medical Officer, will present the company's R&D strategy and vision, focusing on the antibody-drug conjugate (ATTC) platform and its first candidate drug HMPL-A251 [1] Group 2: Future Milestones - According to Guotou Securities, several upcoming milestones for the company are noteworthy, with ATTC platform candidates set to enter clinical development soon [1] - The company plans to complete patient recruitment for the SAFFRON III Phase study of Savolitinib in the second half of 2025, with data expected in the first half of 2026 [1] - The SANOVO China Phase III study patient recruitment is also expected to be completed in the second half of 2025 [1] - The company intends to resubmit the new drug application for Solitomab based on the ESLIM-01 study to the National Medical Products Administration in the first half of 2026 [1] - The first ATTC candidate drug is anticipated to initiate clinical trials in China and globally around the end of 2025 [1]

Core Viewpoint - 361 Degrees is exploring the use of stablecoin payment and settlement solutions for product sales outside mainland China, aiming to enhance payment efficiency and reduce costs for cross-border e-commerce clients [1] Group 1: Company Initiatives - The company has opened an account with an independent third-party service provider specializing in fiat and stablecoin digital payment solutions [1] - The integration of virtual assets is expected to create significant business opportunities for the company [1] Group 2: Market Context - There is an increasing acceptance of cryptocurrencies in the global business community [1] - The company serves numerous cross-border e-commerce and overseas offline store clients who have ongoing needs for local payments and cross-border settlements [1] Group 3: Expected Benefits - The adoption of stablecoin payment methods is anticipated to improve payment efficiency and lower costs, better meeting the needs of cross-border e-commerce clients [1] - This payment method is also expected to help reduce the exchange rate risks faced by the company when transacting with clients outside mainland China [1]

智通财经APP获悉，和誉-B(02256)早盘涨超6%，截至发稿，涨4.92%，报17.93港元，成交额3907.14万 港元。 中金发布研报称，ABSK043 是公司具备全球权益的潜力口服小分子PD-L1 抑制剂。该行认为，公司持 续布局的口服+口服联用方案相较注射+口服联用有望具备更好的患者依从性和安全谱，后续临床进展 值得关注。此外，公司被纳入MSCI全球小盘股指数成分股，有望提升公司的全球资金关注度，或对流 动性产生积极影响。 消息面上，和誉近日宣布，在研口服PD-L1 抑制剂ABSK043 和艾力斯的KRAS G12C抑制剂戈来雷塞片 联用治疗KRAS G12C突变的NSCLC的IND申请在中国获得批准，意味着ABSK043 联用戈来雷塞进入二 期临床。此外，近日公司被纳入MSCI全球小盘股指数成分股。 ...

Group 1 - The core theme of the 2025 Digital Learning Week organized by UNESCO is "The Future of Education with Artificial Intelligence" [1] - NetDragon participated as the only corporate representative in significant events, including the opening ceremony and ministerial roundtable discussions with over 30 education ministers from various countries [5][4] - Dr. Liang Nianjian, Vice Chairman of NetDragon, emphasized the importance of collaboration across academic and national boundaries in the future of education, enabled by technology [1][4] Group 2 - NetDragon showcased its "AI + Education" business achievements and received recognition for its AI digital human technology during the event [8][11] - The company has developed an "AI Production Center" to address global educational resource shortages and imbalances, aiming to produce scalable and culturally adaptable educational content [14][18] - NetDragon has partnered with Thailand's Ministry of Higher Education to launch an AI education platform, supporting the country's "Education 6.0" strategy [15][17] Group 3 - The company has established collaborations with various UN organizations, including the UNESCO IITE, to enhance educational resources and technology [17][18] - NetDragon's initiatives include the development of a national smart education platform in China, collaboration with Belgrade University in Serbia, and digital transformation projects in Cameroon [17][18] - The company aims to continue leveraging its AI Production Center to foster international cooperation and build a global educational community [18]

Core Viewpoint - Hutchison China MediTech Limited (和黄医药) shares rose over 7%, reaching HKD 26.96 with a trading volume of HKD 352 million, following the announcement of a conference in Shanghai to discuss its latest R&D progress [1] Group 1: Company Developments - The company will hold a conference on October 31, 2025, in Shanghai to share its R&D strategies and vision, including an overview of its Antibody-Drug Conjugate (ATTC) platform and its first candidate drug HMPL-A251 [1] - The company’s Executive Vice President and Chief Medical Officer, Dr. Shi Ming, will present during the event [1] Group 2: Clinical Development Milestones - Multiple upcoming milestones for the company are anticipated, with ATTC platform candidate drugs set to enter clinical development soon [1] - The company plans to complete patient recruitment for the SAFFRON III Phase study of Savolitinib by the second half of 2025, with data expected in the first half of 2026 [1] - The SANOVO China Phase III study patient recruitment is also expected to be completed in the second half of 2025 [1] - The company intends to resubmit the new drug application for Solitomab based on the ESLIM-01 study in the first half of 2026 [1] - The first ATTC candidate drug is projected to initiate clinical trials in China and globally around the end of 2025 [1]

和誉-B(02256)早盘涨超6%，截至发稿，涨4.92%，报17.93港元，成交额3907.14万港元。 消息面上，和誉近日宣布，在研口服PD-L1抑制剂ABSK043和艾力斯的KRAS G12C抑制剂戈来雷塞片 联用治疗KRAS G12C突变的NSCLC的IND申请在中国获得批准，意味着ABSK043联用戈来雷塞进入二 期临床。此外，近日公司被纳入MSCI全球小盘股指数成分股。 中金发布研报称，ABSK043是公司具备全球权益的潜力口服小分子PD-L1抑制剂。该行认为，公司持续 布局的口服+口服联用方案相较注射+口服联用有望具备更好的患者依从性和安全谱，后续临床进展值 得关注。此外，公司被纳入MSCI全球小盘股指数成分股，有望提升公司的全球资金关注度，或对流动 性产生积极影响。 ...

据接洽函，就上述出售事项，清盘人已与相关有意方订立保密协议，且于9月9日，清盘人已从其中部分的有意方收到不具约束力的指示性要约。但目前该交 易还处于初步阶段，清盘人未与任何有意方进行谈判。 在历经短暂停牌后，9月12日，恒大物业（06666.HK）复牌高开超38%。随后股价出现回调，截至发稿，报1.18港元，涨幅约28.26%，总市值约127.57亿港 元。 | HK$1.18 +0.26 +28.26% [飞寒时情 | | | 交易中 09–12 | | --- | --- | --- | --- | | 最高：1.29 | 今开： 1.27 | 成交量： 4.86亿股 | 换手： 4.50′ | | 最低： 1.08 | 昨收： 0.92 | 成交额： 5.60亿 | 振幅： 22.8′ | | 52周最高: 1.31 | 量比： 46.32 | 市盈率(动)： 12.33 | 市盈率(TTM | | 52周最低：0.63 | 委比： 57.98% | 市盈率(静)： 11.75 | 市净率： 11 | | 每股收益：0.10 | 股息(TTM)： -- | 总股本： 108.11亿 | 总市值: 12 ...

商业化稳步增长，卡度尼利和依沃西放量带动业绩增长。得益于两款核心双抗卡度尼利单抗和依沃西单 抗进入医保后的快速放量，公司2025H1实现收入14.12亿元，同比+37.75%，以产品销售收入计，销售 收入14.01亿元，同比+49.20%，商业化进展顺利。随着后续产品获批/新增适应症，公司在肿瘤、自 免、代谢等领域持续发力，有望带来充足业绩增量。 智通财经APP获悉，华源证券发布研报称，维持康方生物(09926)"买入"评级，预计公司2025-2027年营 业收入分别为34.19/55.98/85.77亿元。通过DCF方法计算，假设永续增长率为3%，WACC为7.06%，公 司合理股权价值为1875亿港元(汇率取人民币1元=1.07港元)。鉴于公司创新管线出色，商业化强劲，海 外临床确定性逐渐清晰。 康方生物发布2025年半年报，2025H1实现收入14.12亿元，同比+37.75%，归母净利润-5.70亿元;研发费 用7.31亿元，同比+23.06%，销售费用6.70亿元，同比+29.84%、管理费用1.34亿元，同比+34.00%。此 外，康方生物于2025年WCLC大会公布依沃西单抗HARMONi海外数 ...

Core Viewpoint - The report maintains a "buy" rating for Kangfang Biopharma (09926), projecting significant revenue growth from 2025 to 2027, driven by strong commercialization and a promising innovation pipeline [1][2]. Group 1: Financial Performance - Kangfang Biopharma reported a revenue of 14.12 billion yuan for H1 2025, representing a year-on-year increase of 37.75% [1][2]. - The sales revenue from product sales reached 14.01 billion yuan, reflecting a 49.20% year-on-year growth [2]. - R&D expenses were 7.31 billion yuan, up 23.06% year-on-year, while sales and management expenses increased by 29.84% and 34.00%, respectively [1]. Group 2: Product Development and Clinical Trials - The commercialization of core dual antibodies, Kadunil and Ivosidenib, is driving revenue growth, with expectations for further performance improvements as new products and indications are approved [2]. - The WCLC 2025 conference showcased updated overall survival (OS) data for Ivosidenib, indicating a significant improvement in survival benefits, particularly in the North American population [2][3]. - Ongoing clinical trials for Ivosidenib include various cancer types, with a focus on expanding its indications, which could enhance its market potential [3].

招商证券国际将汇通达解读为"独具优势的下沉市场AI+电商领导者"，分析称：公司已在广阔的下沉市 场建立卡位优势，公司核心业务增长稳健、毛利率等盈利能力指标明显改善，印证转型初步成效显著， 同时AI+SaaS成为第二增长引擎，支持汇通达长期乐观的盈利增长前景。 智通财经APP获悉，近日，花旗、第一上海、招商证券国际、浦银国际等相继发布关于汇通达网络 (09878)的最新研报。基于公司2025年中期业绩以及与阿里云达成全栈AI全面合作等，机构普遍认可汇 通达战略转型成果，对公司"AI+智慧供应链"的增长驱动力表达信心，给予"买入"评级，部分目标价至 23港元。 第一上海评论指出，汇通达盈利指标创历史新高，显示出2024年下半年以来的战略转型路径有效、经营 质量持续优化——公司AI+SaaS业务升级显著，凭借与阿里云合作，获得强大技术实力与算力支持，将 联合打造"小店大模型智能体"，整合下沉市场数据资产，推动服务模式向"SaaS软件+AI Agent+内容运 营"升级，且自营商品、自有品牌、头部品牌合作等供应链能力持续升级，为长期增长注入强劲动力。 本月，花旗银行、浦银国际等境外券商最新研报中重申汇通达"买入"评级 ...